BioSpace News Archive

Virios Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2023.

Olink Holding AB announced its unaudited financial results for the first quarter ended March 31, 2023.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, reported financial results for the first quarter ended March 31, 2023, and provided a business update.

Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announce the U.S. Food and Drug Administration has approved the supplemental New Drug Application of REXULTI® for use in the treatment of agitation associated with dementia due to Alzheimer’s disease.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.

POXEL SA announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.

Biophytis SA is announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders’ preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual investors via the PrimaryBid platform up to €0.4M on the other hand.

AlzeCure Pharma AB a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company arranges a Capital Markets Day on May 17 at 10:00-11:30 CET with Professor Bengt Winblad as an invited guest speaker.

Weslie Janeway joins bit.bio board.